Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tacabrutideg vs Investigator's Choice in Relapsed/Refractory CLL/SLL
NCT06846671Phase 3Recruiting
- Sponsor
- BeOne Medicines
- Start
- Apr 2025
- Primary completion
- May 2028
- Modality
- Bivalent/Multivalent Binders, PROTACs (E3 ligase recruitment)
- Countries
- 14
01
Overview
A Phase 3 trial of tacabrutideg in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), sponsored by BeOne Medicines. Started Apr 2025; status: recruiting.
02
Drugs
tacabrutideg
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT06846671.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06846671.